Related Experiment Video
Updated: May 14, 2026

11:58
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Retaining antibodies in tumors with a self-assembling injectable system
Yi Wen1, Harold R Kolonich, Kristen M Kruszewski
1Division of Pharmaceutical Sciences, Duquesne University , Pittsburgh, Pennsylvania 15282, USA.
Molecular Pharmaceutics
|February 20, 2013
Summary
This study introduces an injectable peptide amphiphile membrane that effectively retains therapeutic antibodies in tumors. This novel system enhances antibody retention in vivo, improving localized delivery for potential cancer therapies.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Immunology
Background:
- Therapeutic antibodies, such as IgG, often exhibit short in vivo half-lives, limiting their efficacy.
- Localizing antibodies within target tissues, like tumors, is crucial for enhancing therapeutic outcomes.
- Existing delivery methods struggle with sustained and targeted antibody retention.
Purpose of the Study:
- To evaluate an in situ-forming injectable membrane system for retaining and orienting therapeutic IgG molecules in vivo.
- To assess the biological activity and localization of antibodies within the peptide amphiphile membrane.
- To determine the efficacy of the system in prolonging antibody retention within tumor microenvironments.
Main Methods:
- Development of an injectable aqueous mixture of peptide amphiphiles (EAK16-II, EAKH6) and intermediate proteins (anti-H6 antibody, protein A/G).
- Characterization of the membrane structure using scanning electron microscopy.
- In vitro assessment of IgG capture and biological activity.
- In vivo studies in mice with epithelial tumor lines (4T1) and melanoma (B16) to evaluate IgG retention.
Main Results:
- Scanning electron microscopy confirmed IgG molecule localization on the EAK16-II/EAKH6 membrane.
- Captured IgG retained biological activity in vitro.
- The injectable system successfully coassembled into His-tag displaying materials in vivo.
- Fluorescently labeled IgG was retained in 4T1 mouse mammary tumors for up to 120 hours, compared to 24 hours for free IgG.
- Reduced antibody clearance was observed in B16 melanoma models.
Conclusions:
- The injectable peptide amphiphile membrane system effectively immobilizes and retains therapeutic IgG molecules locally in vivo.
- This approach significantly enhances the in vivo retention time of antibodies within tumor tissues.
- The system holds promise for improving the delivery and efficacy of immune modulatory antibodies in cancer therapy.
Related Concept Videos
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

